Skip to main content
SpringerLink
Log in

Medical Weight Management

  • Chapter
  • First Online:
Bariatric Endoscopy

  • 1262 Accesses

Abstract

There are multiple interventions designed for the treatment of obesity, including various surgical procedures. Still, the fundamental approach to obesity, no matter what other interventional therapy is provided, includes diet, exercise, and behavior management. Additionally, pharmacologic interventions have a long history of moderate success and should be part of the multidimensional approach to the treatment of the obese patient. The goals of medical weight management should be (1) to reduce central abdominal fat stores; (2) to prevent, eliminate, or improve obesity-related complications; (3) to improve quality of life; and (4) to reduce mortality in the obese and overweight populations with comorbidities.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Marti A, Marcos A, Martínez JA. Obesity and immune function relationships. Obes Rev. 2001;2:131–40.

    Article  PubMed  CAS  Google Scholar 

  2. Warnberg J, Morena LA, Mesana MI, Marcos A, Group A. Inflammatory mediators in overweight and obese Spanish adolescents. The AVENA Study. Int J Obes Relat Metab Disord. 2004;28 Suppl 3:S59–63.

    Article  PubMed  Google Scholar 

  3. Warnberg J, Nova E, Moreno LA, et al. Inflammatory proteins are related to total and abdominal adiposity in a healthy adolescent population: the AVENA Study. Am J Clin Nutr. 2006;84:505–12.

    PubMed  CAS  Google Scholar 

  4. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Low-grade systemic inflammation in overweight children. Pediatrics. 2001;107:E13.

    Article  PubMed  CAS  Google Scholar 

  5. Overweight and Obesity. http://www.cdc.gov/women/natstat/overwght.htm. Accessed 21 Mar 2010.

  6. Weight-Control Information Network, NIDDK. Understanding adult obesity. http://win.niddk.nih.gov/publications/understanding.htm. Accessed 21 Mar 2010.

  7. Center for Disease Control. Obesity and overweight for professionals: health consequences. http://www.cdc.gov/obesity/causes/health.html. Accessed 19 Mar 2010.

  8. Stern JS. Preface. In: Thomas P, editor. Weighing the options: criteria for evaluating weight management programs. Washington DC: Institutes of Medicine, National Academic Press; 1995. p. 7–10.

    Google Scholar 

  9. National Heart, Lung and Blood Institute. The practical guide: identification, evaluation, and treatment of overweight and obesity in adults. http://www.nhlbi.nih.gov/guidelines/obesity/prctgd_c.pdf. Accessed 19 Mar 2010.

  10. U.S. Department of Health and Human Services and U.S. Department of Agriculture. Dietary guidelines for Americans 2005. http://www.health.gov/dietaryguidelines/dga2005/document/default.htm. Accessed 19 Mar 2010.

  11. National Heart, Lung and Blood Institute, Washington DC. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. http://www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.pdf. Accessed 19 Mar 2010.

  12. Dwyer JT, Melanson K, Faucon LN. Dietary treatment of obesity. http://www.endotext.org/obesity/obesity18/obesity18.htm. Accessed 20 Mar 2010.

  13. Optifast Weight Loss Program. Optifast the serious solution for weight loss. http://www.optifast.com/Pages/medically_monitored_weight_loss.aspx?s_kwcid=TC|6957|optifast||S||3236986565&gclid=CMe945P-zKACFRKfnAod4hC50A. Accessed 19 Mar 2010.

    Google Scholar 

  14. Medifast Weight Loss Program. http://www.medifast.com. Accessed 19 Mar 2010.

  15. NutriMed Weight Loss Products by Robard. http://www.robard.com/ProgramsProducts/NMProduct/NutriMedProduct.aspx. Accessed 19 Mar 2010.

  16. HMR (Health Management Resources). http://www.ihmonline.com/products_index.aspx. Accessed 19 Mar 2010.

  17. The Cambridge Diet. http://www.cambridgediet.net/physicians.htm. Accessed 19 Mar 2010.

  18. HealthOne. http://www.myhealthone.com/products.html. Accessed 19 Mar 2010.

  19. The HCG Program. http://www.hcgdietplan.org/contact.html. Accessed 19 Mar 2010.

  20. National Institute of Diabetes and Digestive and Kidney Diseases. Very low calorie diets. http://win.niddk.nih.gov/publications/low_calorie.htm. Accessed 19 Mar 2010.

  21. Anderson JW, Grant L, Gotthelf L, et al. Weight loss and long-term follow-up of severely obese individuals treated with an intense behavioral program. Int J Obes. 2007;31:488–93.

    Article  CAS  Google Scholar 

  22. Gilden Tsai A, Wadden T. The evolution of very low calorie diets: an up-date and meta-analysis. Obesity. 2006;14:1283–93.

    Article  Google Scholar 

  23. Saris WH. Very-low calorie diets and sustained weight loss. Obes Res. 2001;9:295S–301.

    Article  PubMed  Google Scholar 

  24. Beals JK. Very-low-calorie diet before bariatric ­surgery reduces risk in superobese patients. http://www.medscape.org/viewarticle/582071. Accessed 21 Mar 2010.

  25. Lewis MC, Phillips ML, Slavotinek JP, et al. Change in liver size and fat content after treatment with Optifast very low calorie diet. Obes Surg. 2006;16:697–701.

    Article  PubMed  Google Scholar 

  26. de Toledo Triffoni-Melo A, Dick-de-Paula I, Portari GV, Jordao AA, Garcia Chiarello, Diez-Garcia RW. Short-term carbohydrate-restricted diet for weight loss on severely obese women. Obes Surg. 2011;21(8):1194–202. Epub ahead of print.

    Article  Google Scholar 

  27. Huerta S, Li Z, Anthony T, et al. Feasibility of a supervised inpatient low-calorie diet program for massive weight loss prior to RYGB in superobese patients. Obes Surg. 2010;20:173–80.

    Article  PubMed  Google Scholar 

  28. Plodkowski RA, St Jeor ST. Medical nutrition therapy for the treatment of obesity. Endocrinol Metab Clin North Am. 2003;32:935–65.

    Article  PubMed  Google Scholar 

  29. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997;336:1117–24.

    Article  PubMed  CAS  Google Scholar 

  30. Hollis JF, Gullion CM, Stephens VJ, et al. Weight loss during the intense intervention phase of the weight loss maintenance trial. Am J Prev Med. 2008;35:118–26.

    Article  PubMed  Google Scholar 

  31. Svetkey LP, Stevens VJ, Brantley PJ, et al. Comparison of strategies for sustained weight loss: the weight loss maintenance randomized controlled trial. JAMA. 2008;12:1139–48.

    Article  Google Scholar 

  32. Weight Watchers. http://www.weightwatchers.com/templates/marketing/Landing_1col_nonav.aspx?PageId=1163821. Accessed 21 Mar 2010.

  33. Jenny Craig Weight Loss Program. http://www.jennycraig.com. Accessed 21 Mar 2010.

  34. Nutrisystem. http://www.nutrisystem.com. Accessed 21 Mar 2010.

  35. LA Weight Loss. http://www.la-weightloss.com/default.aspx. Accessed 21 Mar 2010.

  36. Levine MJ, Jones JM, Lineback DR. Low-carbohydrate diets: assessing the science and knowledge gaps, summary of an ILSI North America Workshop. J Am Diet Assoc. 2006;106(12):2086–94.

    Article  PubMed  CAS  Google Scholar 

  37. The Atkins Diet. http://www.atkins.com/Homepage.aspx. Accessed 21 Mar 2010.

  38. Sears B. The Zone. Los Angeles, CA: Regan Books; 1995.

    Google Scholar 

  39. Agastston A. The South beach diet. New York City, NY: St. Martin’s Griffin; 2005.

    Google Scholar 

  40. Eades MR. Protein power. New York City, NY: Bantam Books; 1997.

    Google Scholar 

  41. Brand-Miller J, Foster-Powell K, McMillan-Price J. The low GI diet revolution: the definitive science-based weight loss plan. Cambridge, MA: Da Capo; 2004.

    Google Scholar 

  42. Sugar Busters. http://sugarbusters.com. Accessed 19 Mar 2010.

  43. Jenkins D, Wolever T, Taylor R, et al. Glycemic Index of foods: a physiological basis for carbohydrate exchange. Am J Clin Nutr. 1981;34:362–6.

    PubMed  CAS  Google Scholar 

  44. Brouns F, Bjorck I, Frayn KN, et al. Glycaemic index methodology. Nutr Res Rev. 2005;18:145–71.

    Article  PubMed  CAS  Google Scholar 

  45. Ludwig DS. The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. JAMA. 2002;287:2414–23.

    Article  PubMed  CAS  Google Scholar 

  46. St Jeor ST, Howard BV, Prewitt E, et al. Dietary protein and weight reduction. A statement for healthcare professionals from the nutrition committee of the council on nutrition, physical activity, and metabolism of the American Heart Association. Circulation. 2001;104:1869–74.

    Article  PubMed  CAS  Google Scholar 

  47. Brierly D, Carlson M, Donnelly A, et al. 1967: the Stillman diet. (History Of Diets, Part 12). (protein diet) (Brief Article). Men’s Fitness. Weider Publications LLC. 2003. Retrieved December 24, 2012 from HighBeam Research: http://www.highbeam.com/doc/1G1-102140891.html

  48. Stern JS. Obesity: food intake. In: Bray GA, editor. Office management of obesity. Philadelphia, PA: Elsevier; 2004.

    Google Scholar 

  49. Stern JS, Hirsch J, Blair SN, et al. Weighing the options: criteria for evaluating weight-management programs. The Committee to develop criteria for evaluating the outcomes of approaches to prevent and treat obesity. Obes Res. 1995;3:591–604.

    Article  PubMed  CAS  Google Scholar 

  50. Foreyt JP, Salas-Salvado J, Caballero B, et al. Weight-reducing diets: are there any differences? Nutr Rev. 2009;67:S99–101.

    Article  PubMed  Google Scholar 

  51. Jéquier E, Bray GA. Low-fat diets are preferred. Am J Med. 2002;113(Suppl):41S–6.

    Article  PubMed  Google Scholar 

  52. Willett WC, Leibel RL. Dietary fat is not a major determinant of body fat. Am J Med. 2002; 113(Suppl): 47S–59.

    Article  PubMed  Google Scholar 

  53. Freedman MR, King J, Kennedy E. Popular diets: a scientific review. Obes Res. 2001;9(Suppl):1S–40.

    Article  PubMed  CAS  Google Scholar 

  54. Skov AR, Toubro S, Rønn B, Holm L, Astrup A. Randomized trial of protein vs. carbohydrate in ad libitum fat reduced diet for the treatment of obesity. Int J Obes Relat Metab Disord. 1999;23:528–36.

    Article  PubMed  CAS  Google Scholar 

  55. Brehm BJ, Seeley RJ, Daniels SR, D’Alessio DA. A randomized trial comparing a very low carbohydrate diet and a calorie-restricted low fat diet on body weight and cardiovascular risk factors in healthy women. J Clin Endocrinol Metab. 2003;88:1617–23.

    Article  PubMed  CAS  Google Scholar 

  56. Foster GD, Wyatt HR, Hill JO, et al. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med. 2003;348:2082–90.

    Article  PubMed  CAS  Google Scholar 

  57. Samaha FF, Iqbal N, Seshadri P, et al. A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med. 2003;348:2074–81.

    Article  PubMed  CAS  Google Scholar 

  58. Yancy Jr WS, Olsen MK, Guyton JR, Bakst RP, Westman EC. A low-carbohydrate ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. Ann Intern Med. 2004;140:769–77.

    PubMed  Google Scholar 

  59. Volek J, Sharman M, Gómez A, et al. Comparison of energy-restricted very low-carbohydrate and low-fat diets on weight loss and body composition in overweight men and women. Nutr Metab (Lond). 2004;1:13.

    Article  CAS  Google Scholar 

  60. Due A, Toubro S, Skov AR, Astrup A. Effect of normal-fat diets, either medium or high in protein, on body weight in overweight subjects: a randomised 1-year trial. Int J Obes Relat Metab Disord. 2004;28:1283–90.

    Article  PubMed  CAS  Google Scholar 

  61. Gardner CD, Kiazand A, Alhassan S, et al. Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A to Z Weight Loss Study: a randomized trial. JAMA. 2007;297:969–77. Erratum, JAMA. 2007;298:178.

    Article  PubMed  CAS  Google Scholar 

  62. Shai I, Schwarzfuchs D, Henkin Y, et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med. 2008;359:229–41.

    Article  PubMed  CAS  Google Scholar 

  63. Noakes M, Keough JB, Foster PR, Clifton PM. Effect of an energy-restricted, high-protein, low-fat diet relative to a conventional low-fat, high-carbohydrate diet on weight loss, body composition, nutritional status, and markers of cardiovascular health in obese women. Am J Clin Nutr. 2005;81:1298–306.

    PubMed  CAS  Google Scholar 

  64. McLaughlin T, Carter S, Lamendola C, et al. Effects of moderate variations in macronutrient composition on weight loss and reduction in cardiovascular disease risk in obese, insulin-resistant adults. Am J Clin Nutr. 2006;84:813–21.

    PubMed  CAS  Google Scholar 

  65. McMillan-Price J, Petocz P, Atkinson F, et al. Comparison of 4 diets of varying glycemic load on weight loss and cardiovascular risk reduction in overweight and obese young adults: a randomized controlled trial. Arch Intern Med. 2006;166:1466–75.

    Article  PubMed  Google Scholar 

  66. Das SK, Gilhooly CH, Golden JK, et al. Long-term effects of 2 energy-restricted diets differing in glycemic load on dietary adherence, body composition, and metabolism in CALERIE: a 1-y randomized controlled trial. Am J Clin Nutr. 2007;85:1023–30.

    PubMed  CAS  Google Scholar 

  67. Lecheminant JD, Gibson CA, Sullivan DK, et al. Comparison of a low carbohydrate and low fat diet for weight maintenance in overweight or obese adults enrolled in a clinical weight management program. Nutr J. 2007;6:36.

    Article  PubMed  CAS  Google Scholar 

  68. Stern L, Iqbal N, Seshadri P, et al. The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. Ann Intern Med. 2004;140:778–85.

    PubMed  Google Scholar 

  69. Dansinger ML, Gleason JA, Griffith JL, Selker JP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA. 2005;293:43–53.

    Article  PubMed  CAS  Google Scholar 

  70. Luscombe-Marsh ND, Noakes M, Wittert GA, Keough JB, Foster P, Clifton PM. Carbohydrate restricted diets high in either monounsaturated fat or protein are equally effective in promoting fat loss and improving blood lipids. Am J Clin Nutr. 2005;81:762–72.

    PubMed  CAS  Google Scholar 

  71. Keogh JB, Luscombe-Marsh ND, Noakes M, Wittert GA, Clifton PM. Long-term weight maintenance and cardiovascular risk factors are not different following weight loss on carbohydrate-restricted diets high in either monounsaturated fat or protein in obese hyperinsulinemic men and women. Br J Nutr. 2007;97:405–10.

    Article  PubMed  CAS  Google Scholar 

  72. Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009;360: 859–73.

    Article  PubMed  CAS  Google Scholar 

  73. Vetter ML, Iqbal N, Dalton-Bakes C, et al. Long-term effects of low-carbohydrate versus low-fat diets in obese persons. Ann Intern Med. 2010;152:334–5.

    PubMed  Google Scholar 

  74. National Institute of Health Medline Plus. Diets. http://www.nlm.nih.gov/medlineplus/diets.html. Accessed 20 Mar 2010.

  75. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial: STORM Study Group: sibutramine trial of obesity reduction and maintenance. Lancet. 2000;356:2119–25.

    Article  PubMed  CAS  Google Scholar 

  76. Torgerson JS, Hauptman J, Boldrin MN, et al. Xenical in the prevention of diabetes in obese subjects (XENDOS) study: randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004; 27:155–61.

    Article  PubMed  CAS  Google Scholar 

  77. Van Gaasl LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor antagonist blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO_Europe study. Lancet. 2005;365: 1389–92.

    Article  CAS  Google Scholar 

  78. Nair RP, Ren J. Pharmacotherapy of obesity—benefit, bias and hyperbole. Curr Med Chem. 2009;16:1888–97.

    Article  PubMed  CAS  Google Scholar 

  79. Haddock CK, Polson WS, Foreyt JP, et al. Effectiveness of Medifast supplements combined with obesity pharmacotherapy: a clinical program evaluation. Eat Weight Disord. 2008;13:95–101.

    PubMed  CAS  Google Scholar 

  80. Luque CA, Rey JA. Sibutramine: a serotonin-norepinephrine-reuptake-inhibitor for the treatment of obesity. Ann Pharmacother. 1999;33:968–78.

    Article  PubMed  CAS  Google Scholar 

  81. Hansen DL, Toubro S, Stock MJ, et al. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes. 1999;23:1016–24.

    Article  CAS  Google Scholar 

  82. Bray GA, Blackburn GL, Ferguson JM, et al. Sibutramine produces dose-related weight loss. Obes Res. 1999;7:189.

    Article  PubMed  CAS  Google Scholar 

  83. Rucker D, Padwal R, Li SK, et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007;335:1194.

    Article  PubMed  CAS  Google Scholar 

  84. European Medicines Association. Press release. http://www.ema.europa.eu/pdfs/human/press/pr/75243109en.pdf. Accessed 21 Mar 2010.

  85. Torp-Pederson C, Caterson I, Coutinho W, et al. Cardiovascular response to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J. 2007;28:2915–23.

    Article  Google Scholar 

  86. Maggioni AP, Caterson I, Coutinho W, et al. Tolerability of sibutramine during a 6-week period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the sibutramine cardiovascular outcomes (SCOUT) trial. J Cardiovasc Pharmacol. 2008;52:393–402.

    Article  PubMed  CAS  Google Scholar 

  87. Food and Drug Administration. Follow-up to the November 2009 early communication about an ongoing safety review of sibutramine, marketed as Meridia. http://www.fda.gov/Drugs/DrugSafety/Postmarket DrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm198206.htm. Accessed 21 Mar 2010.

  88. Meridia (sibutramine): Market Withdrawal Due to Risk of Serious Cardiovascular Events. http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm228830.htm. Accessed 22 Dec 2012.

    PubMed  Google Scholar 

  89. Colman E. Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. Ann Intern Med. 2005;143:380–5.

    PubMed  Google Scholar 

  90. Drent ML, van der Veen EA. Lipase inhibition: a novel concept in the treatment of obesity. Int J Obes. 1993;17:241–4.

    CAS  Google Scholar 

  91. Tolpak H, Zieglar O, Keller U, et al. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced energy diet: early response to treatment predicts weight maintenance. Diabetes Obes Metab. 2005;7:699–708.

    Article  CAS  Google Scholar 

  92. Goldstein DJ, Rampey AHJ, Enas GG, et al. Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obes Relat Metab Disord. 1994;18(3):129–35.

    PubMed  CAS  Google Scholar 

  93. Wadden TA, Bartlett SJ, Foster GD, et al. Sertraline and relapse prevention training following treatment by very-low-calorie diet: a controlled clinical trial. Obes Res. 1995;3:549–57.

    Article  PubMed  CAS  Google Scholar 

  94. Gadde KM, Parker CB, Maner LG, et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res. 2001;9:544–51.

    Article  PubMed  CAS  Google Scholar 

  95. FDA approves Belviq to treat some overweight or obese adults. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm309993.htm. Accessed 22 Dec 2012.

    Article  PubMed  CAS  Google Scholar 

  96. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management. New England Journal of Medicine. 2010;363(3):245–56.

    Article  PubMed  CAS  Google Scholar 

  97. Fidler MC, Sanchez M, Raether B, et al. A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial. Journal of Clinical Endocrinology & Metabolism. 2011;96(10):3067–77.

    Article  PubMed  CAS  Google Scholar 

  98. O’Neil PM, Smith SR, Weissman NJ, et al. Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study. Obesity. 2012;20(7):1426–36.

    Article  PubMed  CAS  Google Scholar 

  99. Bray GA, Hollander P, Klein S, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res. 2003;11:722.

    Article  PubMed  CAS  Google Scholar 

  100. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142:532.

    PubMed  CAS  Google Scholar 

  101. Gadde KM, Franciscy DM, Wagner 2nd HR, Krishnan KR. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA. 2003;289:1820.

    Article  PubMed  CAS  Google Scholar 

  102. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.

    Article  PubMed  CAS  Google Scholar 

  103. Ratner RE, Dickey R, Fineman M, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med. 2004;21:1204–12.

    Article  PubMed  CAS  Google Scholar 

  104. Maggs D, Shen L, Strobel S, et al. Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis. Metabolism. 2003;52: 1638–42.

    Article  PubMed  CAS  Google Scholar 

  105. Poon T, Nelson P, Shen L, et al. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes; a dose-ranging study. Diabetes Technol Ther. 2005;7:466–7.

    Article  Google Scholar 

  106. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes; a 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39–47.

    Article  Google Scholar 

  107. Astrup A, Rossner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomized, double-blind, placebo-controlled study. Lancet 2009;374:1606–16.

    Article  Google Scholar 

  108. Madsbad S. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonist (incretin mimetics)—preclinical and clinical results. Best Pract res Clin Endocrinol Metabol. 2009;23:463–77.

    Article  Google Scholar 

  109. Victoza (loraglutide). http://www.theonlineclinic.co.uk/liraglutide-victoza.asp Accessed 22 Dec 2012.

    Article  Google Scholar 

  110. Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, Niskanen L, Rasmussen MF, Rissanen A, Rössner S, Savolainen MJ, Van Gaal L; NN8022–1807 Investigators. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012;36(6):843–54. doi: 10.1038/ijo.2011.158. Epub 2011 Aug 16. Erratum in: Int J Obes (Lond). 2012;36(6):890. http://www.ncbi.nlm.nih.gov/pubmed/21844879.

    Article  Google Scholar 

  111. Ioannides-Demos LL, Piccenna L, McNeil JJ. Pharmacotherapies for Obesity: Past, Current, and Future Therapies. Journal of Obesity. 2011;2011:1–18.

    Article  Google Scholar 

  112. Rodgers RJTM, Wilding JPH. Anti-obesity drugs: past, present and future. Disease Models and Mechanisms. 2012;5:621–26.

    Article  Google Scholar 

  113. Colman EGJ, Roberts M, Egan A, Weaver J and Rosebraugh C. The FDA’s Assessment of Two Drugs for Chronic Weight Management. N Engl J Med. 2012;367(17):1577–79.

    Article  Google Scholar 

  114. FDA approves weight management drug Qsymia. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312468.htm Accessed 22 Dec 2012.

    Article  Google Scholar 

  115. Saper RB, Eisenberg DM, Phillips RS. Common dietary supplements for weight loss. Am Fam Physician. 2004;70:1731.

    PubMed  Google Scholar 

  116. Cohen PA, McCormick D, Casey C, et al. Imported compounded diet pill use among Brazilian women immigrants in the United States. J Immigr Minor Health. 2007;11:229–36.

    Article  PubMed  Google Scholar 

  117. FDA Alert. FDA warns consumers about Brazilian diet pills found to contain active drug ingredients: Emagrece Sim and Herbathin dietary supplements may be harmful. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108578.htm. Accessed 19 Mar 2010.

  118. Curioni C, Andre C. Rimonabant for overweight or obesity. Cochrane Database Syst Rev. 2006;(4):CD006162.

    Google Scholar 

  119. Bello NT, Zahner MR. Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity. Curr Opin Investig Drugs. 2009;10:1105–16.

    PubMed  CAS  Google Scholar 

  120. Drogrell SA. Tesofensine—a novel potent weight loss medicine. Evaluation of: Astrup A, Bruen L, Jensen TJ, Kroupstrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomized, double-blind, placebo-controlled trial. Lancet 2008;372:1906–1913. Expert Opin Investig Drugs. 2009;18:1043–6.

    Article  CAS  Google Scholar 

  121. Padwal R. Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity. Curr Opin Investig Drugs. 2009;10:1117–25.

    PubMed  CAS  Google Scholar 

  122. F.D.A. declines to approve diet drug. http://www.nytimes.com/2011/02/02/business/02drug.html. Accessed 24 Dec 2012.

    PubMed  CAS  Google Scholar 

  123. Contrave. http://www.orexigen.com/product-candidates/contrave.html. Accessed 22 Dec 2012.

    PubMed  CAS  Google Scholar 

  124. Arrone LJ, Tonstad S, Moreno M, et al. A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study. Int J Obes. 2010;34(5):919–35.

    Article  CAS  Google Scholar 

  125. Addy C, Jumes R, Rosko K, et al. Pharmacokinetics, safety, and tolerability of phentermine in healthy participants receiving taranabant, a novel cannabinoid-1 receptor (CB1R) inverse agonist. J Clin Pharmacol. 2009;49:1228–38.

    Article  PubMed  CAS  Google Scholar 

  126. Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean adults. A randomized, controlled, dose-escalation trial. JAMA. 1999;282:1567–8.

    Article  Google Scholar 

  127. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med. 2003;349:941–8.

    Article  PubMed  CAS  Google Scholar 

  128. Pfafffenger RS, Hyde RT, Wing AL, Hsieh CC. Physical activity, all cause mortality, and longevity of college alumni. N Engl J Med. 1986;3:605–13.

    Google Scholar 

  129. Mansen JE, Hu FB, Rich-Edwards JW, Colditz GA, Stampler MJ, Wollett WC. A prospective study of walking as compared with vigorous exercise in the prevention of coronary artery disease in women. N Engl J Med. 1991;341:650–8.

    Article  Google Scholar 

  130. Blair SN, Kohl III, Barlow CE, et al. Relationship between low cardiorespiratory fitness and mortality in normal-weight, overweight, and obese men. JAMA. 1995;273:1093–8.

    Article  PubMed  CAS  Google Scholar 

  131. National Institute of health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report. Obes Res. 1998;6 Suppl 2:51S–209.

    Google Scholar 

  132. Barlow CE, Kohl HW, Gibbons LW, Blair SN. Physical activity, mortality and obesity. Int J Obes. 1995;19:S41–5.

    Google Scholar 

  133. Tatarrani PA, Ravussin E. Energy metabolism and obesity. In: Wadden TA, Stunkard AJ, editors. Handbook of obesity treatment. New York, NY: Guilford; 2002.

    Google Scholar 

  134. Rennie KL, Wareham NJ. The validation of physical activity instruments for measuring energy expenditure: problems and pitfalls. Public Health Nutr. 1998;1:265–72.

    Article  PubMed  CAS  Google Scholar 

  135. Health and Safety Executive. Health survey for England 2003. http://www.dh.gov.uk/en/Publicationsandstatistics/PublishedSurvey/HealthSurveyForEngland/index.htm.

  136. Wareham N. Physical activity and obesity prevention. Obes Rev. 2007;8 Suppl 1:109–14.

    Article  PubMed  Google Scholar 

  137. Donnely JE, Hill JO, Jacobsen DJ, et al. Effects of a very-low calorie diet and physical-training regimens on body composition and resting metabolic rate in obese females. Am J Clin Nutr. 1991;54:56–61.

    Google Scholar 

  138. Pate RR, Pratt M, Blair SN, et al. Physical activity and public health. A recommendation from the centers for disease control and prevention and the American College of Sports Medicine. JAMA. 1995;273:402–7.

    Article  PubMed  CAS  Google Scholar 

  139. Donnelly JE, Smith B, Jacobsen DJ, et al. The role of exercise for weight loss and maintenance. Best Pract Res Clin Gastroentrol. 2004;18:1009–29.

    Google Scholar 

  140. Jakcicic JM, Clark K, Coleman E, et al. American College of Sports Medicine position stand. Appropriate intervention strategies for weight loss and prevention for regain for adults. Med Sic Sports Exerc. 2001;33:2145–56.

    Article  Google Scholar 

  141. Institute of Medicine. Dietary reference intake for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids. Washington, DC: National Academic Press; 2002. p. 3–5.

    Google Scholar 

  142. Katzmarzyk PT, Janssen I, Ardern CI. Physical inactivity, excess adiposity and premature mortality. Obes Rev. 2003;4:257–90.

    Article  PubMed  CAS  Google Scholar 

  143. Kelm ML, Wing RR, McGuire MT, et al. A descriptive study of individuals successful at long-term weight maintenance of substantial weight loss. Am J Clin Nutr. 1997;66:239–46.

    Google Scholar 

  144. Haskell WL, Lee I-M, Pate RR, et al. Physical activity and public health. Updated recommendation for adults form the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc. 2007;39(8):1423–34.

    Article  PubMed  Google Scholar 

  145. Johannsen DL, Redman LM, Ravussin E. The role of physical activity in maintaining a reduced weight. Nutrition. 2007;9(6):463–71.

    Google Scholar 

  146. Pavlou NK, Krey S, Steffe WP. Exercise as an adjunct to weight loss and maintenance in moderately obese subjects. Am J Clin Nutr. 1989;45(5supp1):1115–23.

    Google Scholar 

  147. Jakicic JM, Winters C, Lang W, Wing RR. Effects of intermittent exercise and use of home exercise equipment on adherence, weight loss, and fitness in overweight woman, a randomized trial. JAMA. 1999;282:1554–60.

    Article  PubMed  CAS  Google Scholar 

  148. Slentz CA, Duscha BD, Johnson JL, et al. Effects of the amount of exercise on body weight, body composition, and measures of central obesity. STRRIDE—a randomized controlled trial. JAMA. 2007;297:2081–91.

    Article  Google Scholar 

  149. Jeffrey RW, Wing RR, Sherwood NE, et al. Physical activity and weight loss: does prescribing higher physical activity goals improve outcome. Am J Clin Nutr. 2007;85:954–9.

    Google Scholar 

  150. Bruun JM, Helge JW, Richelsen B, Stallknecht B. Diet and exercise reduce low-grade inflammation and macrophage infiltration in adipose tissue but not in skeletal muscle in severely obese subjects. Am J Physiol Endocrinol Metab. 2006;209:E961–7.

    Article  CAS  Google Scholar 

  151. Shaw KA, Gennat HC, O’Rourke P, Del Mar C. Exercise for overweight and obesity. The Cochrane Lib. 2009;1:1–104.

    Google Scholar 

  152. Wadden TA, Foster GD. Behavioral treatment of obesity. Med Clin North Am. 2000;84:441–57.

    Article  PubMed  CAS  Google Scholar 

  153. Ravussin E, Lillioja S, Knowler WC, et al. Reduced rate of energy expenditure as a risk factor for body weight gain. N Engl J Med. 1988;318:462–8.

    Article  Google Scholar 

  154. Kanfer FH. Self-monitoring; methodological imitations and clinical applications. J Consult Clin Psychol. 1970;35:148–52.

    Article  Google Scholar 

  155. Carels RA, Darby LA, Rydin S, et al. The relationship between self-monitoring, outcome experiences, difficulties with eating and exercise, and physical activity and weight loss treatment outcomes. Ann Behav Med. 2005;30:182–90.

    Article  PubMed  Google Scholar 

  156. Johnston CA, Tyler C, Foreyt JP, et al. Behavioral management of obesity. Nutrition. 2007;9:448–53.

    Google Scholar 

  157. Berkel LA, Poston WS, Reeves RS, et al. Behavioral interventions and obesity. J Am Diet Assoc. 2005;105 Suppl 1:S35–43.

    Article  PubMed  Google Scholar 

  158. Flechtner-Mors M, Ditschuneit HH, Johnson TD, et al. Metabolic and weight loss effects of long-term dietary intervention in obese patients: four year results. Obes Res. 2000;8:399–402.

    Article  PubMed  CAS  Google Scholar 

  159. Fabricatore AN. Behavioral therapy and cognitive behavioral therapy of obesity: is there a difference? J Am Diet Assoc. 2007;107:92–9.

    Article  PubMed  Google Scholar 

  160. Foster GD, Wadden TA, Vogt RA, et al. What is reasonable weight loss? Patient’s expectations and evaluations of obesity treatment outcomes. J Consult Clin Psychol. 1997;65:79–85.

    Article  PubMed  CAS  Google Scholar 

  161. The Diabetes Prevention Research Group. Achieving weight and activity among diabetes prevention program lifestyle participants. Obes Res. 2004;12:1426–34.

    Article  Google Scholar 

  162. The Diabetes Prevention Program Research Group. Description of lifestyle intervention. Diabetes Care. 2002;346:393–403.

    Google Scholar 

  163. Perri MG, Nezu AM, Mckelvey WF, et al. Relapse prevention training and problem-solving therapy in long-term management of obesity. J Consult Clin Psychol. 2001;69:722–6.

    Article  PubMed  CAS  Google Scholar 

  164. The Look AHEAD Research Group. The Look AHEAD Study; a description of lifestyle intervention and the evidence supporting it. Obesity. 2006;14:737–52.

    Article  Google Scholar 

  165. Wadden TA, Butryn MI, Byrne KJ, et al. Efficacy of lifestyle modification for long-term weight control. Obes Res. 2004;12:151S–61.

    Article  PubMed  Google Scholar 

  166. Tsushima WT, Brindenstine MP, Balfour JF. MMPI-2 scores in the outcome prediction of gastric bypass surgery. Obes Surg. 2004;14:528–32.

    Article  PubMed  Google Scholar 

  167. Clark MM, Balsiger BM, Sletten CD, et al. Psychosocial factors and 2-year outcomes following Bariatric surgery for weight loss. Obes Surg. 2003;13:739–45.

    Article  PubMed  Google Scholar 

  168. Hsu LK, Benotti PN, Dwyer J, et al. Nonsurgical factors that influence outcomes of Bariatric surgery: a review. Psychosom Med. 1998;60:338–46.

    PubMed  CAS  Google Scholar 

  169. Green AE, Dymek-Valentine M, Ptluk S, le Grange D, Alverdy J. Psychosocial outcomes of gastric bypass surgery for patients with and without binge eating. Obes Surg. 2004;14:975–85.

    Article  PubMed  Google Scholar 

  170. Shaw KA, O-Rourke P, Del Mar C, Kennedy J. Psychological interventions for overweight or obesity (review). Cochrane Lib. 2009;1:1–75.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Digestive Diseases, Medical University of South Carolina, Charleston, SC, USA

    Mark DeLegge M.D.

  2. Gastroenterologist/Physician Nutrition Specialist, 36729, Birmingham, AL, 38236-6729, USA

    Jeanette Newton Keith M.D.

Authors
  1. Mark DeLegge M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeanette Newton Keith M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeanette Newton Keith M.D. .

Editor information

Editors and Affiliations

  1. Harvard Medical School, Division of Gastroenterology,, Brigham and Women's Hospital, 75 Francis St, ASB2, Boston, 02115, Massachusetts, USA

    Christopher C. Thompson

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

DeLegge, M., Keith, J.N. (2013). Medical Weight Management. In: Thompson, C. (eds) Bariatric Endoscopy. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-1710-2_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-1710-2_3

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-1709-6

  • Online ISBN: 978-1-4419-1710-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation